肺部、肠道菌群与结核病发生发展的研究进展

doi:10.19871/j.cnki.xfcrbzz.2024.04.013

摘要/Abstract

摘要： 结核病是由结核分枝杆菌（mycobacterium tuberculosis,Mtb）感染引起的慢性传染病,对人类的危害不可小觑。人体肺部和肠道定植有数以万亿计的微生物菌群,微生物菌群在结核病的临床研究中逐渐被重视。本文通过搜索分析近几年发表于Pubmed、Embase、中国知网、万方医学网等数据库的相关文献,对健康人群和结核病患者肺部和肠道菌群的组成及特征等方面进行了阐述,对菌群在结核病中的作用机制以及抗结核分枝杆菌治疗对菌群的影响进行了相关分析。结果发现：健康人群和结核病患者肺部菌群组成不同;Mtb感染后改变了肠道菌群的α多样性;菌群基于肠–肺轴、免疫系统、宿主部分代谢产物参与结核病的发生发展;抗结核分枝杆菌治疗会使肠道菌群的结构组成发生改变;“菌群治疗”作为一种新型的辅助治疗在结核病领域值得关注。菌群与结核病相互作用关系的深入研究可为结核病防治工作提供新的思路。

关键词: 肺部菌群, 肠道菌群, 肠-肺轴, 结核病

Abstract: Tuberculosis is a chronic infectious disease caused by mycobacterium tuberculosis (mycobacterium tuberculosis, Mtb). It poses a significant threat to human health.The human lungs and intestinal tract are home to trillions of microorganisms. As a result, microbiological flora has received increasing attention in clinical research on tuberculosis. This has been achieved through summaries of relevant literature published in recent years in Pubmed, Embase, CNKI, and the Wanfang database. These summaries provide information on the composition and characteristics of lung and intestinal flora, the role of flora in tuberculosis, and the impact of tuberculosis mycobacterium treatment on the microbiota.Research has demonstrated that: the lung flora composition differs between TB patients and the healthy population; the intestinal flora's α diversity changed following Mtb infection; the immune system, the intestinal-lung axis, and host metabolites play a role in the development of tuberculosis; the structural composition of the intestinal flora is altered by treatment with anti-tuberculosis mycobacterium; "flora therapy" is a new adjuvant therapy in the field of tuberculosis. Additional research on the relationship between microbiota and tuberculosis may yield novel prevention strategies.

Key words: Pulmonary flora, Intestinal flora, Intestinal-lung axis, Tuberculosis

中图分类号:

R521.9

刘钰, 孙小琴, 刘婷, 徐亚丽, 虎维东. 肺部、肠道菌群与结核病发生发展的研究进展[J]. 新发传染病电子杂志, 2024, 9(4): 61-67.

Liu Yu, Sun Xiaoqin, Liu Ting, Xu Yali, Hu Weidong. Progress in the study of the pulmonary and intestinal flora and the occurrence and development of tuberculosis[J]. Electronic Journal of Emerging Infectious Diseases, 2024, 9(4): 61-67.

参考文献

[1] 卢春容, 谭卫国, 陆普选, 等. 2023年WHO全球结核病报告:全球与中国关键数据分析[J/CD]. 新发传染病电子杂志, 2023, 8(6):73-78.
[2] BAUGHMAN RP, THORPE JE, STANECK J, et al.Use of the protected specimen brush in patients with endotracheal or tracheostomy tubes[J]. Chest, 1987, 91(2):233-236.
[3] LI Z, LI Y, SUN Q, et al.Targeting the Pulmonary Microbiota to Fight against Respiratory Diseases[J].Cells, 2022, 11(5):916.
[4] BLAINEY PC, MILLA CE, CORNFIELD DN, et al. Quantitative analysis of the human airway microbial ecology reveals a pervasive signature for cystic fibrosis[J]. Sci Transl Med, 2012, 4(153):153ra130.
[5] DICKSON RP, ERB-DOWNWARD JR, FREEMAN CM, et al.Bacterial Topography of the Healthy Human Lower Respirator Tract[J]. mBio, 2017, 8(1):e02287-16.
[6] ESHETIE S, VAN SOOLINGEN D.The respiratory microbiota: new insights into pulmonary tuberculosis[J]. BMC Infect Dis, 2019, 19(1):92.
[7] PAULO AC, LANÇA J, ALMEIDA ST, et al. The upper respiratory tract microbiota of healthy adults is affected by Streptococcus pneumoniae carriage, smoking habits, and contact with children[J]. Microbiome, 2023, 11(1):199.
[8] ZHAN D, LI D, YUAN K, et al.Characteristics of the pulmonary microbiota in patients with mild and severe pulmonary infection[J]. Front Cell Infect Microbiol, 2023, 13:1227581.
[9] WYPYCH TP, WICKRAMASINGHE LC, MARSLAND BJ, et al.The influence of the microbiome on respiratory health[J]. Nat Immunol, 2019, 20(10):1279-1290.
[10] PANT A, DAS B, ARIMBASSERI GA, et al.Host microbiome in tuberculosis: disease, treatment, and immunity perspectives[J]. Front Microbiol, 2023, 14:1236348.
[11] SATHKUMARA HD, EATON JL, FIELD MA, et al.A murine model of tuberculosis/type 2 diabetes comorbidity for investigating the microbiome, metabolome and associated immune parameters[J]. Animal Model Exp Med, 2021, 4(2):181-188.
[12] KRAEMER JG, RAMETTE A, AEBI S, et al.Influence of Pig Farming on the Human Nasal Microbiota: Key Role of Airborne Microbial Communities[J]. Appl Environ Microbiol, 2018, 84(6):e02470-17.
[13] NAIDOO CC, NYAWO GR, WU BG, et al.The microbiome and tuberculosis: state of the art, potential applications, and defining the clinical research agenda[J]. Lancet Respir Med, 2019, 7(10):892-906.
[14] 邱倩,刘东鑫,刘春法, 等. 采用宏基因组学分析肺结核患者与健康人群呼吸道微生物菌群的特征[J].中国防痨杂志, 2020, 42(10):1100-1108.
[15] CUI Z, ZHOU Y, LI H, et al.Complex sputum microbial composition in patients with pulmonary tuberculosis[J]. BMC Microbiol, 2012, 12:276.
[16] WU J, LIU W, HE L, et al.Sputum microbiota associated with new, recurrent and treatment failure tuberculosis[J]. PLoS One, 2013, 8(12):e83445.
[17] ZHOU Y, LIN F, CUI Z,et al.Correlation between Either Cupriavidus or Porphyromonas and Primary Pulmonary Tuberculosis Found by Analysing the Microbiota in Patients' Bronchoalveolar Lavage Fluid[J].PLoS One,2015,10(5):e0124194.
[18] VÁZQUEZ-PÉREZ JA, CARRILLO CO, IÑIGUEZ-GARCÍA MA, et al.Alveolar microbiota profile in patients with human pulmonary tuberculosis and interstitial pneumonia[J]. Microb Pathog,2020,139:103851.
[19] HUANG Y, TANG JH, CAI Z, et al.Alterations in the nasopharyngeal microbiota associated with active and latent tuberculosis[J]. Tuberculosis (Edinb),2022,136:102231.
[20] XIAO G, CAI Z, GUO Q, et al.Insights into the Unique Lung Microbiota Profile of Pulmonary Tuberculosis Patients Using Metagenomic Next-Generation Sequencing[J]. Microbiol Spectr,2022,10(1):e0190121.
[21] SALA C, BENJAK A, GOLETTI D, et al.Multicenter analysis of sputum microbiota in tuberculosis patients[J]. PLoS One, 2020, 15(10):e0240250.
[22] ARUMUGAM M, RAES J, PELLETIER E, et al.Enterotypes of the human gut microbiome[J]. Nature, 2011, 473(7346):174-80.
[23] TANG Q, JIN G, WANG G, et al.Current Sampling Methods for Gut Microbiota: A Call for More Precise Devices[J]. Front Cell Infect Microbiol, 2020, 10:151.
[24] 潘燕珊. 抗结核治疗与肠道微生态的相互作用[D]. 广州:广州医科大学, 2021.
[25] YE S, WANG L, LI S, et al.The correlation between dysfunctional intestinal flora and pathology feature of patients with pulmonary tuberculosis[J]. Front Cell Infect Microbiol,2022,12:1090889.
[26] WANG S, YANG L, HU H,et al.Characteristic gut microbiota and metabolic changes in patients with pulmonarytuberculosis[J]. Microb Biotechnol, 2022, 15(1):262-275.
[27] HU Y, FENG Y, WU J, et al.The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients[J]. Front Cell Infect Microbiol, 2019, 9:90.
[28] MAJI A, MISRA R, DHAKAN DB, et al.Gut microbiome contributes to impairment of immunity in pulmonary tuberculosis patients by alteration of butyrate and propionate producers[J]. Environ Microbiol, 2018, 20(1):402-419.
[29] WANG J, XIONG K, ZHAO S, et al.Long-Term Effects of Multi-Drug-Resistant Tuberculosis Treatment on Gut Microbiota and Its Health Consequences[J]. Front Microbiol, 2020, 11:53.
[30] DANG AT, MARSLAND BJ.Microbes, metabolites, and the gut-lung axis[J]. Mucosal Immunol, 2019, 12(4):843-850.
[31] SOUTHAM DS, DOLOVICH M, O'BYRNE PM, et al. Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia[J]. Am J Physiol Lung Cell Mol Physiol, 2002, 282(4):L833-9.
[32] CHEN LW, CHEN PH, HSU CM, et al.Commensal microflora contribute to host defense against Escherichia coli pneumonia through Toll-like receptors[J]. Shock, 2011, 36(1):67-75.
[33] TANG J, XU L, ZENG Y, et al.Effect of gut microbiota on LPS-induced acute lung injury by regulatingthe TLR4/NF-kB signaling pathway[J]. Int Immunopharmacol,2021,91:107272.
[34] WINGLEE K, ELOE-FADROSH E, GUPTA S, et al.Aerosol Mycobacterium tuberculosis infection causes rapid loss of diversity in gut microbiota[J]. PLoS One, 2014, 9(5):e97048.
[35] NEGI S, PAHARI S, BASHIR H, et al.Gut Microbiota Regulates Mincle Mediated Activation of Lung Dendritic Cells to Protect Against Mycobacterium tuberculosis[J]. Front Immunol, 2019, 10:1142.
[36] NAMASIVAYAM S, KAUFFMAN KD, MCCULLOCH JA, et al.Correlation between Disease Severity and the Intestinal Microbiome in Mycobacterium tuberculosis-Infected Rhesus Macaques[J]. mBio, 2019, 10(3):e01018-19.
[37] LUO M, LIU Y, WU P, et al.Alternation of Gut Microbiota in Patients with Pulmonary Tuberculosis[J]. Front Physiol, 2017, 8:822.
[38] YANG F, YANG Y, CHEN L, et al.The gut microbiota mediates protective immunity against tuberculosis via modulation of lncRNA[J]. Gut Microbes, 2022, 14(1): 2029997.
[39] YANG F, YANG Y, CHEN Y, et al.MiR-21 Is Remotely Governed by the Commensal Bacteria and Impairs Anti-TB Immunity by Down-Regulating IFN-γ[J]. Front Microbiol, 2021, 11:512581.
[40] MAJLESSI L, SAYES F, BUREAU JF, et al.Colonization with Helicobacter is concomitant with modified gut microbiota and drastic failure of the immune control of Mycobacterium tuberculosis[J]. Mucosal Immunol, 2017, 10(5):1178-1189.
[41] PERRY S, DE JONG BC, SOLNICK JV, et al.Infection with Helicobacter pylori is associated with protection against tuberculosis[J]. PLoS One, 2010, 5(1):e8804.
[42] YAO Y, CAI X, FEI W, et al.The role of short-chain fatty acids in immunity, inflammation and metabolism[J]. Crit Rev Food Sci Nutr, 2022, 62(1):1-12.
[43] SATHKUMARA HD, EATON JL, FIELD MA, et al.A murine model of tuberculosis/type 2 diabetes comorbidity for investigating the microbiome, metabolome and associated immune parameters[J]. Animal Model Exp Med, 2021, 4(2):181-188.
[44] ASHIQUE S, DE RUBIS G, SIROHI E, et al.Short Chain Fatty Acids: Fundamental mediators of the gut-lung axis and their involvement in pulmonary diseases[J]. Chem Biol Interact, 2022, 368:110231.
[45] GÖSCHL L, SCHEINECKER C, BONELLI M. Treg cells in autoimmunity: from identification to Treg-based therapies[J]. Semin Immunopathol,2019,41(3):301-314.
[46] LACHMANDAS E, VAN DEN HEUVEL CN, DAMEN MS, et al.Diabetes Mellitus and Increased Tuberculosis Susceptibility: The Role of Short-Chain Fatty Acids[J]. J Diabetes Res, 2016, 2016:6014631.
[47] YU Z, SHEN X, WANG A, et al.The gut microbiome: A line of defense against tuberculosis development[J]. Front Cell Infect Microbiol, 2023, 13:1149679.
[48] NEGATU DA, YAMADA Y, XI Y, et al.Gut Microbiota Metabolite Indole Propionic Acid Targets Tryptophan Biosynthesis in Mycobacterium tuberculosis[J]. mBio, 2019, 10(2):e02781-18.
[49] LIU N, LIU J, ZHENG B,et al.Gut microbiota affects sensitivity to immune-mediated isoniazid-induced liver injury[J]. Biomed Pharmacother,2023,160:114400.
[50] ZHANG M, SHEN L, ZHOU X, et al.The Microbiota of Human Lung of Pulmonary Tuberculosis and the Alteration Caused by Anti-tuberculosis Drugs[J]. Curr Microbiol, 2022, 79(11):321.
[51] 林媛, 谭守勇, 蔡杏珊, 等. 肺结核患者抗结核治疗前后呼吸道菌群生态的变化[J].分子诊断与治疗杂志, 2023, 15(12):2229-2232, 2241.
[52] HU Y, YANG Q, LIU B,et al.Gut microbiota associated with pulmonary tuberculosis and dysbiosis caused by anti-tuberculosis drugs[J]. J Infect,2019,78(4):317-322.
[53] MENG R, DONG W, GAO J, et al.Clostridium, Bacteroides and Prevotella associates with increased fecal metabolites Trans-4-Hydroxy-L-proline and Genistein in active pulmonary tuberculosis patients during anti-tuberculosis chemotherapy with isoniazid-rifampin-pyrazinamide-ethambutol (HRZE)[J]. Indian J Microbiol, 2022, 62(3):374-383.
[54] CAO D, LIU W, LYU N, et al.Gut Mycobiota Dysbiosis in Pulmonary Tuberculosis Patients Undergoing Anti-Tuberculosis Treatment[J]. Microbiol Spectr, 2021, 9(3):e0061521.
[55] WIPPERMAN MF, FITZGERALD DW, JUSTE MAJ,et al.Antibiotic treatment for Tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed[J]. Sci Rep, 2017, 7(1):10767.
[56] KHAN N, MENDONCA L, DHARIWAL A,et al.Intestinal dysbiosis compromises alveolar macrophage immunity to Mycobacterium tuberculosis[J]. Mucosal Immunol, 2019, 12(3):772-783.
[57] LIU X, WU Y, MAO C, et al.Host-acting antibacterial compounds combat cytosolic bacteria[J]. Trends Microbiol, 2022, 30(8):761-777.
[58] TEGEGNE BA, KEBEDE B.Probiotics, their prophylactic and therapeutic applications in human health development: A review of the literature[J]. Heliyon,2022,8(6):e09725.
[59] RAHIM MA, SEO H, KIM S,et al.In vitro anti-tuberculosis effect of probiotic Lacticaseibacillus rhamnosus PMC203 isolated from vaginal microbiota[J]. Sci Rep,2022,12(1):8290.
[60] JIANG L, WANG J, XU L, et al.Lactobacillus casei modulates inflammatory cytokines and metabolites during tuberculosis treatment: A post hoc randomized controlled trial[J]. Asia Pac J Clin Nutr, 2022, 31(1):66-77.
[61] 杨舒琪,李锋. 肺结核患者肠道菌群失调的研究进展[J/CD].新发传染病电子杂志,2023,8(2):82-85.